Fish oil is the main source of the two long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is sold in two very different forms: as an over-the-counter dietary supplement, and as FDA-approved prescription drugs such as Vascepa (icosapent ethyl, a purified EPA) and Lovaza (a concentrated mix of EPA and DHA).
The most important fact is that the two forms have different evidence. The prescription products are approved to lower very high triglycerides, and icosapent ethyl at 4 g/day is also approved to cut cardiovascular events in statin-treated, high-risk patients. Large trials of ordinary 1 g/day fish oil capsules in the general population and in people with diabetes found no reduction in major cardiovascular events. High doses also carry a consistent signal for atrial fibrillation.
This page summarizes what the FDA labels, the large outcome trials and meta-analyses report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Class | Long-chain omega-3 polyunsaturated fatty acids (EPA, DHA) |
| Prescription products | Vascepa (icosapent ethyl, EPA only; approved 2012); Lovaza (omega-3-acid ethyl esters, EPA + DHA; approved 2004) |
| Supplements | Fish oil capsules and liquids; not approved by FDA before marketing |
| Route | Oral |
| Labeled prescription dose | 4 g/day with food (Vascepa and Lovaza) |
| Doses in major trials | 840 mg/day EPA + DHA (VITAL, ASCEND); 4 g/day (REDUCE-IT, STRENGTH) |
| Half-life | EPA ≈89 h in plasma (Vascepa label) |
| Main lipid effect | Lowers triglycerides; DHA-containing Lovaza can raise LDL cholesterol |
| Key safety signal | Atrial fibrillation, greater at doses above 1 g/day; bleeding |
| WADA status | Not on the 2026 Prohibited List |
What it is
EPA (20 carbons, 5 double bonds) and DHA (22 carbons, 6 double bonds) are “omega-3” fatty acids because their first double bond sits three carbons from the end of the chain. The body incorporates them into cell membranes and blood lipids. In the bloodstream, almost all EPA is carried inside phospholipids, triglycerides and cholesteryl esters, and under 1% circulates as the free fatty acid (Vascepa label).
The products on the market differ in what they contain and in how they are regulated:
| Product | What it contains | Regulatory status (US) |
|---|---|---|
| Vascepa (icosapent ethyl) | Ethyl ester of EPA only; 0.5 g and 1 g capsules | Prescription drug, FDA-approved 2012 |
| Lovaza (omega-3-acid ethyl esters) | At least 900 mg omega-3 ethyl esters per 1 g capsule: ≈465 mg EPA and ≈375 mg DHA | Prescription drug, FDA-approved 2004 |
| Omega-3 carboxylic acids (tested in STRENGTH) | EPA and DHA as free fatty acids | Studied at 4 g/day in STRENGTH |
| Fish oil supplements | Variable EPA and DHA content | Dietary supplement; no premarket FDA approval |
Under the Dietary Supplement Health and Education Act, FDA “does not have the authority to approve dietary supplements before they are marketed,” and there is no legal limit on the amount of an ingredient per serving (FDA Q&A on dietary supplements). Product content, purity and dose are therefore set by the manufacturer.
How it works in the body
Both prescription labels describe the triglyceride-lowering mechanism as not completely understood. Proposed mechanisms include less triglyceride production in the liver (through inhibition of the enzyme DGAT and reduced fat synthesis), more fatty acid burning (β-oxidation) and faster triglyceride clearance through lipoprotein lipase (Vascepa label; Lovaza label). The Vascepa label adds that EPA inhibits platelet aggregation under some laboratory conditions, which is one reason bleeding is monitored.
The Vascepa label reports these kinetics for EPA:
| Parameter | Value |
|---|---|
| Absorption | Ester is removed during absorption; EPA enters the blood mainly via the lymphatic system |
| Time to peak | ≈5 h after an oral dose |
| Volume of distribution | ≈88 L |
| Metabolism | Mainly β-oxidation in the liver, like dietary fat; cytochrome P450 is a minor pathway |
| Plasma clearance | 684 mL/h |
| Elimination half-life | ≈89 h |
| Renal excretion | None |
The long half-life means blood and tissue levels build up over weeks of daily use rather than after a single dose. The Lovaza label reports a dose-dependent rise in EPA in serum phospholipids, while the rise in DHA was smaller and not dose-dependent.
Approved medical use (prescription products)
Vascepa (icosapent ethyl)
The label approves icosapent ethyl for two uses in adults (Vascepa label):
- as an add-on to maximally tolerated statin therapy, to reduce the risk of heart attack, stroke, coronary revascularization and hospitalization for unstable angina in people with triglycerides of 150 mg/dL or more and either established cardiovascular disease, or diabetes plus 2 or more other risk factors;
- as an add-on to diet to lower triglycerides in severe hypertriglyceridemia (500 mg/dL or more).
The labeled dose is 4 g/day, taken as 2 g twice daily with food, with capsules swallowed whole. The label notes that the drug’s effect on pancreatitis risk in severe hypertriglyceridemia has not been determined.
Lovaza (omega-3-acid ethyl esters)
Lovaza is approved only as an add-on to diet to lower triglycerides in adults with severe hypertriglyceridemia (500 mg/dL or more), at 4 g/day as one dose or two 2 g doses (Lovaza label). Its label states that its effects on cardiovascular death and illness, and on pancreatitis, have not been determined.
Triglyceride lowering in the label trials
| Trial (label) | Population | Triglycerides | LDL cholesterol |
|---|---|---|---|
| Vascepa 4 g/day vs placebo, 12 weeks (n = 151) | Baseline TG 500–2,000 mg/dL | −33% placebo-adjusted (95% CI −47 to −22) | −2% placebo-adjusted (not significant) |
| Lovaza 4 g/day vs placebo, 6 and 16 weeks (n = 84) | Baseline TG 500–2,000 mg/dL | −45% vs +7% on placebo | +45% vs −5% on placebo |
The LDL rise with Lovaza is why its label advises monitoring LDL cholesterol. The EPA-only product did not show that rise in its severe-hypertriglyceridemia trial.
What the research shows
The four major outcome trials
These four randomized, double-blind trials shaped how omega-3 products are viewed today:
| Trial | Population (n) | Product and daily dose | Comparator | Follow-up | Primary outcome result |
|---|---|---|---|---|---|
| VITAL | US adults ≥50 (men) or ≥55 (women), no cardiovascular disease (25,871) | Fish oil 1 g capsule: 460 mg EPA + 380 mg DHA | Placebo | 5.3 years (median) | Major CV events HR 0.92 (95% CI 0.80–1.06) |
| ASCEND | Diabetes without cardiovascular disease (15,480) | 1 g capsule: 460 mg EPA + 380 mg DHA | Olive oil | 7.4 years (mean) | Serious vascular events 8.9% vs 9.2%; rate ratio 0.97 (95% CI 0.87–1.08) |
| REDUCE-IT | Statin-treated, established CV disease or diabetes plus risk factors, TG 135–499 mg/dL (8,179) | Icosapent ethyl (EPA) 4 g | Mineral oil | 4.9 years (median) | 17.2% vs 22.0%; HR 0.75 (95% CI 0.68–0.83) |
| STRENGTH | Statin-treated, high CV risk, high TG and low HDL (13,078) | Omega-3 carboxylic acids (EPA + DHA) 4 g | Corn oil | ≈3.5 years (median); stopped early for low probability of benefit | 12.0% vs 12.2%; HR 0.99 (95% CI 0.90–1.09) |
Sources: Manson et al., NEJM 2019; ASCEND, NEJM 2018; Bhatt et al., NEJM 2019; Nicholls et al., JAMA 2020. Capsule composition for VITAL and ASCEND from the trial report and Gencer et al., Circulation 2021.
Supplement-dose fish oil: VITAL and ASCEND
VITAL tested a 1 g/day fish oil capsule (840 mg EPA + DHA) in 25,871 healthy older US adults, alongside a separate vitamin D comparison (see Vitamin D3). It found no reduction in its primary cardiovascular outcome or in invasive cancer (HR 1.03, 95% CI 0.93–1.13) (Manson et al., NEJM 2019). All-cause death was unchanged (HR 1.02).
Among secondary outcomes, total heart attacks were lower (HR 0.72, 95% CI 0.59–0.90), but stroke (HR 1.04) and cardiovascular death (HR 0.96) were not. The investigators did not correct secondary or subgroup analyses for multiple testing and advised caution in interpreting them. No excess bleeding was observed.
ASCEND gave the same 1 g/day dose or olive oil to 15,480 people with diabetes but no known cardiovascular disease for a mean of 7.4 years (ASCEND, NEJM 2018). Serious vascular events (8.9% vs 9.2%) and death from any cause (9.7% vs 10.2%) did not differ significantly.
High-dose prescription omega-3: REDUCE-IT and STRENGTH
REDUCE-IT randomized 8,179 statin-treated patients with raised triglycerides (71% with established cardiovascular disease) to icosapent ethyl 4 g/day or placebo (Bhatt et al., NEJM 2019). The results, as shown in the Vascepa label:
| Outcome | Icosapent ethyl | Placebo | HR (95% CI) |
|---|---|---|---|
| Primary 5-part composite | 17.2% | 22.0% | 0.75 (0.68–0.83) |
| CV death, heart attack or stroke | 11.2% | 14.8% | 0.74 (0.65–0.83) |
| Heart attack (fatal or nonfatal) | 6.1% | 8.7% | 0.69 (0.58–0.81) |
| Stroke (fatal or nonfatal) | 2.4% | 3.3% | 0.72 (0.55–0.93) |
| Cardiovascular death | 4.3% | 5.2% | 0.80 (0.66–0.98) |
Triglycerides fell by a median of 18% at one year on icosapent ethyl, compared with a 2% rise on placebo. That modest triglyceride change was much smaller than the drop in events, so the mechanism of benefit remains uncertain.
The REDUCE-IT placebo was pharmaceutical-grade mineral oil, and this has been debated. In a biomarker substudy, markers linked to atherosclerosis rose over time in the mineral oil group but changed little on icosapent ethyl (Ridker et al., Circulation 2022). At 12 months, for example, LDL cholesterol rose by 10.9% and high-sensitivity C-reactive protein by 21.9% in the mineral oil group. The authors stated that the effect of these changes on the trial’s overall result is uncertain.
STRENGTH tested 4 g/day of an EPA plus DHA product (omega-3 carboxylic acids) against corn oil in 13,078 statin-treated, high-risk patients (Nicholls et al., JAMA 2020). It was stopped early after an interim analysis showed a low probability of benefit, with the primary outcome in 12.0% vs 12.2% of patients. Gastrointestinal side effects were more common on the omega-3 product (24.7% vs 14.7%).
Why REDUCE-IT and STRENGTH disagree is unresolved. The trials differ in the product (pure EPA vs EPA plus DHA) and in the comparator (mineral oil vs corn oil).
An earlier Japanese trial, JELIS, also supports EPA alone. It randomized 18,645 people with high cholesterol to 1,800 mg/day EPA plus a statin or a statin alone (Yokoyama et al., Lancet 2007). Major coronary events were 2.8% vs 3.5%, a 19% relative reduction. JELIS was open-label (no placebo), and its participants already ate a lot of fish.
Pooled evidence
A 2020 Cochrane review pooled 86 randomized trials with 162,796 participants lasting at least 12 months (Abdelhamid et al., Cochrane 2020):
| Outcome (long-chain omega-3 vs lower intake) | Risk ratio (95% CI) | Certainty |
|---|---|---|
| All-cause death | 0.97 (0.93–1.01) | High |
| Cardiovascular events | 0.96 (0.92–1.01) | High |
| Cardiovascular death | 0.92 (0.86–0.99) | Moderate |
| Coronary heart disease events | 0.91 (0.85–0.97) | Low |
| Stroke | 1.02 (0.94–1.12) | Moderate |
The review concluded that long-chain omega-3s have little or no effect on death or overall cardiovascular events, may slightly reduce coronary heart disease events, and lower triglycerides by about 15% in a dose-dependent way.
Muscle and recovery
Interest in fish oil for muscle comes mainly from small trials in older adults:
- In 16 older adults, 8 weeks of omega-3 supplementation did not change resting muscle protein synthesis but increased the rise in synthesis during an infusion of amino acids and insulin (Smith et al., AJCN 2011).
- In 60 healthy adults aged 60–85, 6 months of Lovaza 4 g/day (1.86 g EPA + 1.50 g DHA) vs corn oil increased thigh muscle volume by 3.6% (95% CI 0.2–7.0%), handgrip by 2.3 kg and 1RM strength by 4.0% (Smith et al., AJCN 2015). Only 44 participants completed the study.
Larger pooled analyses are less positive:
| Meta-analysis | Population | Finding |
|---|---|---|
| Cornish et al., Nutrients 2022 | Older adults, 16 studies | No effect on lean mass (SMD 0.09); improved lower-body strength (SMD 0.54) and chair-rise tests |
| Therdyothin et al., Nutr Rev 2025 | 8 randomized trials | No effect on muscle protein synthesis (SMD 0.03, 95% CI −0.35 to 0.40) |
| Silva et al., Nutrition 2026 | Healthy adults | No clear effect on fat-free mass (SMD 0.26, 95% CI −1.14 to 1.66) or strength (SMD −0.02); very low certainty |
In short, there is no good evidence that fish oil builds muscle in healthy, younger, trained people. A modest benefit for strength and function in older adults is possible but not established.
Side effects and risks
Atrial fibrillation
Atrial fibrillation (AF) is an irregular, often rapid heart rhythm that raises stroke risk. It is the clearest safety signal for omega-3 products.
- REDUCE-IT: hospitalization for AF or flutter occurred in 3.1% on icosapent ethyl vs 2.1% on placebo (Bhatt et al., NEJM 2019). The Vascepa label lists this as a warning, with HR 1.5 (95% CI 1.14–1.98), and notes higher rates in people with prior AF.
- STRENGTH: new-onset AF in 2.2% vs 1.3% on corn oil (HR 1.69, 95% CI 1.29–2.21), as tabulated by Gencer et al.
- Lovaza label: in 663 people with existing paroxysmal or persistent AF, Lovaza (8 g/day for 7 days, then 4 g/day) was linked to more frequent recurrences of symptomatic AF, especially in the first 2–3 months (combined HR 1.25, 95% CI 1.00–1.40).
- VITAL (840 mg/day): in a dedicated analysis of 25,119 participants, incident AF was 3.7% vs 3.4% (HR 1.09, 95% CI 0.96–1.24), not a significant difference (Albert et al., JAMA 2021).
A 2021 meta-analysis of 7 cardiovascular outcome trials (81,210 patients) put the pieces together (Gencer et al., Circulation 2021):
| Dose group | AF hazard ratio (95% CI) |
|---|---|
| All trials | 1.25 (1.07–1.46) |
| ≤1 g/day | 1.12 (1.03–1.22) |
| Over 1 g/day | 1.49 (1.04–2.15) |
| Per additional 1 g/day | 1.11 (1.06–1.15) |
The AF risk therefore appears to rise with dose. In most of these trials AF was not a centrally adjudicated outcome.
Bleeding
In REDUCE-IT, any bleeding occurred in 12% on icosapent ethyl vs 10% on placebo, and serious bleeding in 3% vs 2% (Vascepa label). Bleeding was more common in people also taking aspirin, clopidogrel or warfarin. Both prescription labels state that omega-3s can prolong bleeding time and advise monitoring patients on anticoagulants or antiplatelet drugs. VITAL found no excess bleeding at 840 mg/day.
Other side effects and lab changes
| Product | Common side effects (label) |
|---|---|
| Vascepa (outcome trial) | Musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation |
| Vascepa (triglyceride trials) | Joint pain, throat pain |
| Lovaza (23 pooled trials) | Burping 4% vs 1%; indigestion 3% vs 2%; altered taste 4% vs under 1% |
The Lovaza label also reports rises in the liver enzyme ALT and in LDL cholesterol in some patients, and advises periodic ALT, AST and LDL checks. Both labels advise periodic liver enzyme monitoring in people with liver impairment.
Fish allergy and who should not use it
Both prescription products are contraindicated in people with known hypersensitivity to the product. Both are made from fish oil, and their labels state it is not known whether people allergic to fish or shellfish are at higher risk of reactions. Safety and effectiveness in children have not been established, and data in pregnancy are insufficient to identify a drug-related risk.
Interactions
In label studies, icosapent ethyl 4 g/day did not change the levels of omeprazole, rosiglitazone, warfarin or atorvastatin, nor warfarin’s anticoagulant effect. Lovaza 4 g/day did not change the levels of simvastatin, atorvastatin or rosuvastatin. The main interaction concern is additive bleeding risk with blood thinners rather than a change in drug levels.
Quality and contamination
Because supplements are not approved before sale, their quality varies. Two issues have been studied:
- Mercury: a 2003 analysis of 5 US fish oil brands found mercury from undetectable to negligible levels, similar to normal human blood (Foran et al., Arch Pathol Lab Med 2003).
- Oxidation (rancidity): of 171 North American omega-3 supplements tested, 50% exceeded voluntary industry limits for oxidation markers. Flavored products, bulk oils and children’s products were more oxidized than plain capsules (Jackowski et al., J Nutr Sci 2015). Six of the seven authors listed an affiliation with a company, Pivotal Therapeutics.
When menhaden fish oil is added to conventional foods, FDA regulations cap its use so that total EPA plus DHA intake does not exceed 3.0 g per person per day, and set a mercury limit of 0.5 ppm in the oil (21 CFR 184.1472). This rule applies to food ingredients, not to supplement capsules.
Fish oil is not named on the WADA 2026 Prohibited List.
Key takeaways
- Two different products. Prescription icosapent ethyl and Lovaza are FDA-approved 4 g/day drugs; fish oil supplements are not approved before sale and vary in content.
- Supplement doses did not prevent heart disease. VITAL and ASCEND, with more than 41,000 participants combined, found no reduction in major cardiovascular events at 840 mg/day of EPA plus DHA.
- High-dose EPA is the exception. REDUCE-IT showed a 25% relative reduction in events with icosapent ethyl 4 g/day, but STRENGTH found no benefit from 4 g/day of EPA plus DHA, and the mineral oil placebo in REDUCE-IT remains debated.
- Triglycerides fall reliably. Lovaza lowered triglycerides by about 45% in severe hypertriglyceridemia but raised LDL cholesterol; the Cochrane review estimates about 15% lower triglycerides overall.
- Atrial fibrillation risk rises with dose. Pooled trials show about 12% higher risk at 1 g/day or less and about 49% higher above 1 g/day; bleeding also rises at 4 g/day.
- Little evidence for muscle building. Small trials in older adults suggest modest gains in strength, but meta-analyses find no clear effect on lean mass or muscle protein synthesis.
Sources
- Amarin Pharma. Vascepa (icosapent ethyl) capsules, prescribing information, revised 03/2026. DailyMed.
- Waylis Therapeutics. Lovaza (omega-3-acid ethyl esters) capsules, prescribing information, revised 11/2024. DailyMed.
- Food and Drug Administration. Questions and answers on dietary supplements. FDA.
- Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32. PubMed.
- ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–1550. PubMed.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. PubMed.
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–2280. PubMed.
- Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022;146(5):372–379. PubMed.
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098. PubMed.
- Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(3):CD003177. PubMed.
- Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981–1990. PubMed.
- Albert CM, Cook NR, Pester J, et al. Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial. JAMA. 2021;325(11):1061–1073. PubMed.
- Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93(2):402–412. PubMed.
- Smith GI, Julliand S, Reeds DN, et al. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr. 2015;102(1):115–122. PubMed.
- Cornish SM, Cordingley DM, Shaw KA, et al. Effects of omega-3 supplementation alone and combined with resistance exercise on skeletal muscle in older adults: a systematic review and meta-analysis. Nutrients. 2022;14(11):2221. PubMed.
- Therdyothin A, Prokopidis K, Galli F, et al. The effects of omega-3 polyunsaturated fatty acids on muscle and whole-body protein synthesis: a systematic review and meta-analysis. Nutr Rev. 2025;83(2):e131–e143. PubMed.
- Silva AMF, Simões MO, Artioli GG. Omega-3 supplementation shows no clear benefit for fat-free mass or muscle strength in healthy adults: a systematic review and meta-analysis of randomized controlled trials. Nutrition. 2026;153:113378. PubMed.
- Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch Pathol Lab Med. 2003;127(12):1603–1605. PubMed.
- Jackowski SA, Alvi AZ, Mirajkar A, et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci. 2015;4:e30. PubMed.
- Menhaden oil. 21 CFR 184.1472. eCFR.
- World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.